Blood immune cells rose during MS relapses in study

Credibility

Interest

Share:2 min read

Key Takeaway

People having an MS relapse had more of a certain immune cell in their blood than people whose MS was quiet.

What They Found

Researchers found more of these immune cells in the blood of people having an MS relapse than in people whose MS was quiet. Mice missing these cells developed a milder MS-like disease than other mice. Fewer B cells, a type of immune cell, entered the brains of mice missing these cells. In lab tests, B cells from the brains of sick mice prompted other immune cells to release more signals that drive inflammation. A drug that blocked a signal used by B cells erased the improvement in mice missing these cells.

Who Should Care and Why

This study included people with MS, mice, and cells studied in a lab. The people with MS were in either relapse or remission (a period when MS is quiet). Their blood results suggest these immune cells may reflect whether MS is active. The mouse experiments explored why these cells might affect an MS-like disease. The drug findings came from mice, not from treatment of people with MS.

Important Considerations

The abstract describes two groups of people with MS but does not say how many people took part. It does not show whether a blood test using these cells can reliably detect a relapse in an individual. You cannot tell from the mouse results whether blocking the same signal would affect MS in people.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Science translational medicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News